Mantle cell lymphoma of the prostate is rare and is seldom encountered in general urologic practice. It either arises primarily from the prostate or is a result of metastatic spread from another site. This specific type of lymphoma has an aggressive course and may respond poorly to traditional chemotherapy with frequent relapses. Mantle cell lymphoma occurs in middle age or older, which is also when symptoms of benign prostatic enlargement begin in men. This overlap makes the diagnosis of lymphoma of the prostate difficult and makes the treatment more complex. We describe a case of mantle cell lymphoma of the prostate that caused significant enlargement and bladder outlet obstruction with urinary retention. The obstruction was treated with holmium laser enucleation of the prostate with good functional results. L ymphoma of the prostate is an exceedingly rare entity, with less than 200 reported cases (1). Mantle cell lymphoma (MCL) of the prostate is even less common, with only 7 reported cases (2-6). We report a case of a 59-yearold man with MCL of the prostate that was discovered after holmium laser enucleation of the prostate.
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CASE PRESENTATION
A 59-year-old man was referred by his primary care provider for progressive lower urinary tract symptoms. He had been treated for MCL during the prior 8 years with several clinical relapses. Initially he was treated with traditional chemotherapy, and he received chemotherapy with autologous stem cell transplantation 2 years later for disease recurrence. He did well for many years and was successfully treated with salvage bendamustine/rituximab chemotherapy 6 months prior to his prostate surgery. A follow-up computed tomography scan after this latest treatment showed complete radiographic resolution of his lymphoma.
Several months after completing the most recent chemotherapy, his symptoms of nocturia, hesitancy, urgency, and frequency eventually progressed to complete urinary retention. Digital rectal exam revealed an enlarged prostate without nodules and was overall considered benign. His prostate-specifi c antigen level was 1.2 ng/mL, and gland size measured 107 cm 3 , which yielded a PSA density of 0.01 ng/mL/cm 3 . Cystoscopy demonstrated a 5 cm-long prostate with bilobar enlargement and grade 3 trabeculation of the bladder. After discussing treatment options, the patient chose to undergo holmium laser enucleation of the prostate for relief of his urinary obstruction.
During his surgery, the prostate tissue was very soft and required minimal laser energy to make the incisions in the prostatic adenoma. Establishing planes was challenging, especially in the 6 o'clock groove and lateral prostatic capsular dissection. It took 60 minutes to enucleate the gland and 20 minutes to morcellate all of the tissue. Th e total weight of enucleated tissue was 189 g. After an uncomplicated recovery in the hospital, the patient improved signifi cantly and was voiding spontaneously without any residual volume on postoperative day 1.
Th e resected prostate tissue was infi ltrated by a homogenous population of medium-sized lymphoid cells with irregular nuclear contours. Th e lymphoid cells were positive for Pax-5, CD20, CD5, and Cyclin D1, consistent with recurrent MCL (Figure) . Th e morphological features were not suggestive of the aggressive variants of MCL. Th is diagnosis was confi rmed by immunohistochemistry as well as DNA fl uorescence in situ hybridization analysis of his previously biopsied bone marrow, which was positive for t(11;14).
Th e patient was not restaged after this pathology fi nding. No more chemotherapy treatments were planned, and he was transitioned to hospice care.
DISCUSSION
Lymphoma of the prostate is exceedingly rare, with less than 200 cases reported, and the majority of cases are discovered at autopsy (6) . Th e largest case series comprising the pathology database of fi ve university hospitals spanning an aggregate of 200 years has documented only 62 cases of lymphoma of the prostate (1) . A further review of 5962 autopsy specimens revealed that only 49 (0.82%) of the patients had non-Hodgkin's lymphoma of the prostate (3).
Mantle cell lymphoma of the prostate gland treated with holmium laser enucleation Preston A. Milburn, MD, Christian T. Cable, MD, Sean Trevathan, MD, and Marawan M. El Tayeb, MD MCL is an even rarer entity of prostatic lymphoma, with only 7 cases reported in the literature (1-7). Th ese patients typically present with progressive lower urinary tract symptoms consisting of urgency, frequency, nocturia, and hematuria, and the lymphoma is discovered after microscopic analysis of resected prostate tissue. Treatment of known lymphoma of the prostate typically consists of chemotherapy or radiation, with surgery reserved for mechanical obstruction. Lymphoma of the prostate is classifi ed as either primary or secondary based on the location discovered and lack of extraprostatic disease (8). Our patient clearly had secondary lymphoma given his long history with the disease.
MCL is a distinct subtype of B-cell non-Hodgkin's lymphoma and comprises 3% to 10% of all lymphomas occurring in middle-aged to older individuals, with a median age of about 60 years and a marked male predominance (9) . MCL generally has an aggressive clinical course with frequent relapses after conventional chemotherapy.
Th e dense, diff use, and monotonous infi ltrate seen histologically can reliably be diff erentiated from other benign confounders (chronic or granulomatous prostatitis) as well as other mature B-cell lymphomas by positive immunohistochemical staining for Cyclin D1, CD5, CD23, and CD10, as well as negativity for BCL6. 
